Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Complication of Injection Clear all
Completed Phase 2 Interventional Results available

Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer

NCT02965976
View directory record Official record
Conditions
Esophageal Carcinoma
Interventions
Botulinum Toxin Type A, Esophagectomy, Quality-of-Life Assessment
Biological · Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 4, 2026, 9:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)

NCT01552408
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Sep 4, 2026, 9:17 AM EDT
Completed Phase 2 Interventional

Triamcinolone Acetonide Injections to Treat Diabetic Macular Edema

NCT00231023
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Peribulbar Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 4, 2026, 9:17 AM EDT
Completed Phase 4 Interventional Results available

Liposomal Bupivacaine Single-Injection Interscalene Block vs. Continuous Interscalene Block for Primary Total Shoulder Arthroplasty

NCT05005260
View directory record Official record
Conditions
Pain, Postoperative, Brachial Plexus Block
Interventions
Bupivacaine HCl, Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 4, 2026, 9:17 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)

NCT03666923
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
THR-687 dose level 1, THR-687 dose level 2, THR-687 dose level 3
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 4, 2026, 9:17 AM EDT
Terminated Phase 2 Interventional Results available

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

NCT02855268
View directory record Official record
Conditions
Alport Syndrome
Interventions
lademirsen (SAR339375), Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Minneapolis, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 4, 2026, 9:17 AM EDT
Withdrawn Phase 4 Interventional

Articaine vs Lidocaine for Pediatric Dental Procedures

NCT03318952
View directory record Official record
Conditions
Anesthesia, Dental, Pain, Postoperative
Interventions
lidocaine, articaine
Drug
Lead sponsor
Boston University
Other
Eligibility
4 Years to 14 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 4, 2026, 9:17 AM EDT
Completed Phase 4 Interventional

Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis

NCT00053547
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End Stage Renal Disease
Interventions
paricalcitol injection
Drug
Lead sponsor
Abbott
Industry
Eligibility
2 Years to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
6
States / cities
Stanford, California • Miami, Florida • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2006 · Synced Sep 4, 2026, 9:17 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT03917472
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Brolucizumab, Aflibercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
74
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Sep 4, 2026, 9:17 AM EDT
Completed Phase 3 Interventional

Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-Operative Pain Following Abdominoplasty

NCT03997838
View directory record Official record
Conditions
Pain, Postoperative
Interventions
VVZ-149 Injections, Placebo
Drug
Lead sponsor
Vivozon, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
5
States / cities
Phoenix, Arizona • Anaheim, California • Dayton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Sep 4, 2026, 9:17 AM EDT
Withdrawn Phase 1 Interventional

OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer

NCT04941378
View directory record Official record
Conditions
Ovarian Cancer
Interventions
OTL38, intraoperative imaging camera system
Drug · Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2022 · Synced Sep 4, 2026, 9:17 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty

NCT01683071
View directory record Official record
Conditions
Postoperative Pain
Interventions
Placebo, EXPAREL 67 mg, EXPAREL 133 mg, EXPAREL 266 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
30
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 4, 2026, 9:17 AM EDT
Completed Phase 3 Interventional Results available

Study of APD421 as PONV Treatment (no Prior Prophylaxis)

NCT02449291
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
APD421, Placebo
Drug
Lead sponsor
Acacia Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 4, 2026, 9:17 AM EDT
Terminated Phase 3 Interventional

ssTAP vs TAP Catheters in TAH

NCT02525900
View directory record Official record
Conditions
Postoperative Pain
Interventions
Wound Infiltration, TAP Blocks, TAP Catheters
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Sep 4, 2026, 9:17 AM EDT
Withdrawn Phase 1 Interventional

E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia

NCT04411134
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
E7 TCR
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Sep 4, 2026, 9:17 AM EDT
Completed Phase 1 Interventional

Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema

NCT00886808
View directory record Official record
Conditions
Diffuse Diabetic Macular Edema
Interventions
iCo-007 Intravitreal Injection
Drug
Lead sponsor
iCo Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Sep 4, 2026, 9:17 AM EDT
Recruiting Phase 1Phase 2 Interventional

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

NCT05413850
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms, Prostatic Neoplasms, Prostatic Diseases
Interventions
Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only)
Drug · Diagnostic Test
Lead sponsor
Blue Earth Therapeutics Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
Miami, Florida • Atlanta, Georgia • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 4, 2026, 9:17 AM EDT
Not listed Phase 4 Interventional

Trigger Point Injections and Pelvic Rehabilitation for the Treatment of Pelvic Floor Myalgia and Sexual Pain

NCT02022722
View directory record Official record
Conditions
Dyspareunia
Interventions
Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride, Pelvic Rehabilitation
Drug · Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2013 · Synced Sep 4, 2026, 9:17 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

NCT02614547
View directory record Official record
Conditions
Severe Postpartum Depression
Interventions
SAGE-547, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Atlanta, Georgia • Worcester, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 4, 2026, 9:17 AM EDT
Recruiting Phase 4 Interventional

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

NCT06445946
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions
Metformin, Insulin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
24
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 4, 2026, 9:17 AM EDT
Completed No phase listed Observational

Supraclavicular Blocks for Post-Operative Pain Control in Supracondylar Fracture Fixation, a Retrospective Analysis of Single Shot Catheter Techniques

NCT02210429
View directory record Official record
Conditions
Acute Pain, Pain, Postoperative
Interventions
Elbow Fracture Fixation
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Up to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 4, 2026, 9:17 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Paracervical Injection and Opioid Use After Vaginal Hysterectomy for Prolapse

NCT07213635
View directory record Official record
Conditions
Opioid Use, Surgical Recovery, Vaginal Hysterectomy, Prolapse Pelvic, Postoperative Pain
Interventions
Bupivacaine-epinephrine, Normal saline
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 4, 2026, 9:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema

NCT02949024
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
IVT Aflibercept, SC CLS-TA
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Mountain View, California • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 4, 2026, 9:17 AM EDT
Completed Phase 2 Interventional

RE104 Safety and Efficacy Study in Postpartum Depression

NCT06342310
View directory record Official record
Conditions
Postpartum Depression
Interventions
RE104 for Injection
Drug
Lead sponsor
Reunion Neuroscience Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Tucson, Arizona • Santa Monica, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 4, 2026, 9:17 AM EDT